GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Archives for Antimicrobial Agents and Chemotherapy

Pharmacogene sequencing of a gabonese population with severe Plasmodium falciparum malaria reveals multiple novel variants with putative relevance for antimalarial treatment

  • Authors: Leyre Pernaute-Lau, Ayola Akim Adegnika, Yitian Zhou, Jeannot F Zinsou, Jose Pedro Gil, Sanjeev Krishna, Peter G Kremsner, Volker M Lauschke, Thirumalaisamy P Velavan
  • Publication Year: 2021
  • Journal: Antimicrobial Agents and Chemotherapy, 65(7), art e00275-21
  • Link: https://doi.org/10.1128/AAC.00275-21

ABSTRACT Malaria remains one of the deadliest diseases in Africa, particularly for children. While successful in reducing morbidity and mortality, antimalarial treatments are also a major cause of adverse drug reactions (ADRs). Host genetic variation in genes involved in drug disposition or toxicity constitutes an important determinant of ADR risk and can prime for parasite […]
Read More

An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors

  • Authors: Theys K, Libin PJK, Van Laethem K, Abecasis AB
  • Publication Year: 2019
  • Journal: Antimicrobial Agents and Chemotherapy
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/31109980

Viral pathogens causing global disease burdens are often characterized by high rates of evolutionary changes. The extensive viral diversity at baseline can shorten the time to escape from therapeutic or immune selective pressure and alter mutational pathways. The impact of genotypic background on the barrier to resistance can be difficult to capture, particularly for agents […]
Read More

Emergence of high-level colistin resistance in an acinetobacter baumannii clinical isolate mediated by inactivation of the global regulator H-NS

  • Authors: Deveson Lucas D, Crane B, Wright A, Han ML, Moffatt J, Bulach D, Gladman SL, Powell D, Aranda J, Seemann T, Machado D, Pacheco T, Marques T, Viveiros M, Nation R, Li J, Harper M, Boyce JD
  • Publication Year: 2018
  • Journal: Antimicrobial Agents and Chemotherapy
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/29712662

Colistin is a crucial last-line drug used for the treatment of life-threatening infections caused by multidrug-resistant strains of the Gram-negative bacterium Acinetobacter baumannii However, colistin-resistant A. baumannii isolates can still be isolated following failed colistin therapy. Resistance is most often mediated by the addition of phosphoethanolamine (pEtN) to lipid A by PmrC, following missense mutations in the pmrCAB operon encoding PmrC […]
Read More

Synergy between circular bacteriocin AS-48 and ethambutol against mycobacterium tuberculosis

  • Authors: Aguilar-Pérez C, Garcia B, Rodrigues L, Vitoria A, Cebrián R, Deboosère N, Song O-R, Brodin P, Maqueda M, Aínsaa JA
  • Publication Year: 2018
  • Journal: Antimicrobial Agents and Chemotherapy
  • Link: https://aac.asm.org/content/early/2018/07/03/AAC.00359-18

The increasing incidence of multi-drug resistant Mycobacterium tuberculosis and the very few drugs available for treatment is promoting the discovery and development of new molecules that could help in the control of this disease. Bacteriocin AS-48 is an antibacterial peptide produced by Enterococcus faecalis, active against several Gram-positive bacteria. We have found that AS-48 was active against Mycobacterium tuberculosis, […]
Read More

Plasmodium falciparum genetic diversity in continental Equatorial Guinea before and after introduction of artemisinin based combination therapy

  • Authors: Arez AP, Berzosa P, de Sousa B, Guerra M, Mendes C, Ndong-Mabale N, Neres R, Salgueiro P
  • Publication Year: 2017
  • Journal: Antimicrobial Agents and Chemotherapy
  • Link: http://aac.asm.org/content/61/1/e02556-15.full%20

Efforts to control malaria may affect malaria parasite genetic variability and drug resistance, the latter of which is associated with genetic events that promote mechanisms to escape drug action. The worldwide spread of drug resistance has been a major obstacle to controlling Plasmodium falciparum malaria, and thus the study of the origin and spread of associated mutations […]
Read More

  • 1
  • 2
  • 3
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok